Intuitive Surgical, Inc.

The filings tell a mostly consistent story of growth. Net income attributable to Intuitive Surgical reached $2.86 billion in 2025 against $2.32 billion in 2024, and operating cash flow of $3.03 billion produced an operating cash flow to net income ratio of 1.06, meaning cash generation roughly matched reported earnings. The Beneish M-Score of -2.514 is below the -1.78 threshold and is not in the elevated manipulation-risk zone. This is a screening result rather than proof that the numbers are accurate, but it does not raise a flag on the 2025 figures. The Altman Z-double-prime score of 12.01 is in the safe zone, meaning the model sees low distress risk from the balance sheet, with total assets of $20.46 billion against liabilities of $2.52 billion at year end 2025. The model is a statistical estimate and does not describe near-term liquidity. Management's narrative centers on the installed base of da Vinci and Ion systems, the Quintuple Aim, and an expanding clinical sales team. The MD&A notes that capital sales have lengthy cycles affected by hospital budgeting. The share repurchase of $2,094.3 million in the first nine months of 2025 and the drop in property, plant, and equipment purchases to $377.3 million from $799.2 million are facts a reader can weigh against the inventory build. Readers may want to look at the next 10-K for the inventory trend, the joint venture with Fosun Pharma, and the competitor product launches named in the competition section.

Catalyst.According to the 2025 10-K MD&A, the business is driven by da Vinci surgical systems and Ion endoluminal systems, with 2025 revenue split 68% domestic and 32% outside the U.S. Total revenue reached $10.06 billion in 2025, up from $8.35 billion in 2024, a 20.5% increase, and operating income rose to $2.95 billion from $2.35 billion. Management describes recurring instrument, accessory, and service revenue alongside system placements. The nine-month 10-Q shows product revenue of $6,048.4 million and service revenue of $1,150.1 million for the nine months ended September 30, 2025, compared with $4,978.9 million and $959.7 million a year earlier.

Hidden risk.The 10-Q balance sheet shows inventory rising to $1,781.9 million at September 30, 2025, from $1,487.2 million at December 31, 2024, a 19.8% increase in nine months. Inventory purchases absorbed $810.4 million of operating cash in the nine-month cash flow statement. The 10-K competition section names Johnson & Johnson and Medtronic plc, expects increasing competition in China, and warns of possible pricing pressure. The filing also says some components come from sole-sourced or single-sourced suppliers and are bought through purchase orders rather than long-term supply agreements. Readers may want to look at whether inventory keeps pace with system placements.